[Skip to Content]
[Skip to Content Landing]
March 20, 1981

Regression of Pituitary Prolactinoma With Bromocriptine Administration

Author Affiliations

From the Departments of Internal Medicine (Drs Velentzas and Carras), and Neurosurgery (Dr Vassilouthis), 401 Military Hospital, Athens, Greece.

JAMA. 1981;245(11):1149-1150. doi:10.1001/jama.1981.03310360041022

IT HAS been demonstrated that treatment with bromocriptine mesylate can reduce the size of pituitary prolactinomas.1,2 The actual mechanism by which this is achieved remains obscure, although bromocriptine has been shown to reduce the mitotic rate of the tumor in rats.3 In man, bromocriptine, an ergot derivative and dopamine agonist, has a potent inhibitory action on prolactin secretion and, in patients with hyperprolactinemia, it lowers serum prolactin levels and restores gonadal function.1

We treated a patient with a sizeable pituitary prolactinoma with bromocriptine alone. A remarkable reduction of the tumor size was achieved in addition to the reversal of the biochemical features.

Report of a Case  A 20-year-old man was referred to us for further investigation of hypogonadism and occasional diplopia, which occurred on his looking to the left. His medical history revealed that he had not yet reached puberty and libido was absent. Otherwise, his medical